Subscribe To
VOR / How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
VOR News
By GlobeNewsWire
September 25, 2023
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that more_horizontal
By GlobeNewsWire
April 18, 2023
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that more_horizontal
By Zacks Investment Research
March 28, 2023
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not more_horizontal
By Seeking Alpha
March 27, 2023
Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells. more_horizontal
By Pulse2
March 24, 2023
Vor Bio Announces Q4 And FY 2022 Results
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year t more_horizontal
By GlobeNewsWire
April 25, 2022
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPC more_horizontal